Cancer Australia’s latest figures put a hard number on a trend most Queenslanders have long suspected: melanoma incidence has climbed dramatically over the past four decades, even as survival outcomes have improved substantially over the same period.
The long-term trend in the data
Age-standardised melanoma incidence rose from 29.6 to 65 cases per 100,000 people between 1982 and 2019, a 120 percent increase. In raw numbers, 2019 alone recorded 15,628 new melanoma diagnoses nationally, split between 9,134 men and 6,494 women.
Part of that rise reflects genuinely improved detection rather than a proportional increase in actual disease occurrence, since dermoscopy and structured screening programs have become far more widespread since the 1980s. Separating true incidence growth from detection-driven growth remains an ongoing challenge for epidemiologists working with this kind of long-run data.
Lifetime risk figures reflect that gender gap clearly: men face a 1 in 14 chance of a melanoma diagnosis compared with 1 in 21 for women, while mortality risk by age 85 sits at 1 in 164 for men versus 1 in 340 for women.
Researchers attribute part of the gender gap to differences in sun protection behaviour and healthcare-seeking patterns, with men historically less likely to apply sunscreen consistently or present early when a suspicious spot appears, a pattern that shows up across multiple national datasets, not just Cancer Australia’s figures.
The survival numbers tell a more encouraging story
Despite rising incidence, five-year melanoma survival improved from 90 percent in the 1990 to 1994 period to 93.6 percent for people diagnosed between 2015 and 2019. That gain reflects earlier detection and improved treatment options rather than any drop in underlying risk.
Cancer Australia’s data also shows a notable decline in age-specific melanoma rates among people under 40 since the late 1990s, a trend widely attributed to sustained SunSmart-style prevention programs reaching younger Australians earlier in life.
That generational divide is a useful case study in what effective, sustained public health messaging can achieve. Australians who grew up with sun safety education from childhood are now showing measurably lower age-specific melanoma rates than earlier generations did at the same age, even as overall population incidence keeps climbing.
Why early detection still carries the most weight
The gap between rising incidence and improving survival is explained almost entirely by detection timing. Melanomas caught early are overwhelmingly more treatable than those found after they’ve progressed, which is why survival curves have moved even as diagnosis numbers haven’t slowed.
That gap is the practical argument for regular, structured monitoring rather than waiting for a visibly changing mole to prompt action. Comprehensive Dermatology Clinics Australia checks using dermoscopy and photographic mole mapping are designed specifically to catch the kind of early-stage changes that raw incidence statistics can’t show on their own.
The survival gain from 90 to 93.6 percent over roughly 25 years might look incremental on paper, but applied across tens of thousands of annual diagnoses, it represents a meaningful number of lives where earlier detection was almost certainly the deciding factor between a straightforward excision and a far more serious course of treatment.
With skin cancer treatment now costing the health system more than $1.72 billion annually, the economic argument for early detection lines up with the clinical one. Whatever incidence does over the next decade, the survival data makes clear that timing of diagnosis, not the disease itself, remains the biggest variable within a patient’s control. The 120 percent rise since 1982 is unlikely to reverse quickly, but the survival curve shows what happens when detection keeps pace with it.
